ASXC - Asensus: Consider The Whole Picture

• Asensus' Senhance robotic platform helps surgeons with high-precision tasks, without necessarily crowding the operation room during COVID times.
• Given the favorable response and feedback from surgeons, the company anticipates to sell more of its systems and accessories.
• Competition is fierce for the tiny medical device play, but in view of product strength and with advanced AI capabilities, it still makes for a suitable investment proposition.
• However, the company is spending heavily to generate growth, but equipped with a high amount of cash, it has time to consider options which can add to shareholder's value.
• Overvalued when considering the Price to Sales metric, but undervalued as per the Price to Book one, Asensus is a buy after the dip and some forthcoming catalysts.

For further details see: